FONT-SIZE Plus   Neg

MEDA Says FDA Approved Dymista - Quick Facts

MEDA AB (MDABF.PK) said the U.S. Food and Drug Administration has approved Dymista, a new patented product for treatment of seasonal allergic rhinitis, or SAR. In several clinical studies, Dymista has consistently showed a rapid and more complete symptom relief than standard treatment.

Anders Lönner, CEO of Meda AB, said, "...The approval of Dymista represents an important achievement for Meda's clinical development groups in the US and Europe. Meda's franchise in the allergy area is strengthened and gives opportunities for the company to grow and establish collaborations in the field. Dymista will be available in the US during the second half of 2012".

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Electric car maker Tesla Motors Inc. (TSLA), Wednesday reported a profit for the third quarter beating Wall Street estimates by a large margin, driven primarily by record production and deliveries. Shares of the company gained over 5 percent in extended hours after the company reaffirmed its delivery... Auvi-Q, the rival for EpiPen, will be coming back in 2017, pharmaceutical company Kaleo announced on Wednesday. Auvi-Q is a epinephrine injection used to treat life-threatening allergic reactions, including anaphylaxis, in people who are at risk for or have a history of serious allergic reactions. Auvi-Q... Uber's self-driving technology start-up Otto has partnered with Anheuser-Busch InBev to complete the world's first shipment by a self-driving truck. Otto said in a blog post that the company and Anheuser-Busch delivered 51,744 cans of Budweiser beer from Fort Collins, through downtown Denver, to Colorado Springs.
comments powered by Disqus
Follow RTT